Please disregard the headline "Gilead Sciences Proposed to Acquire CymaBay for $32.50 Per Shr in Cash or a Total Equity Value of $4.3B," at 4:46 p.m. ET. The.
By Dean Seal Shares of HOOKIPA Pharma surged after the company said Gilead Sciences bought 15 million of its shares at about $1.42 apiece. The stock was up.
By Zaeem Shoaib The U.S. Food and Drug Administration is investigating certain CAR T cancer therapies based on reports that they might cause a type of white.
By Colin Kellaher Gilead Sciences is investing another $200 million in clinical-stage biotechnology company Arcellx as part of an expansion of the duo's.